Corona Remedies Limited · NSE:CORONA
Corona Remedies — Q4 FY26 Earnings Presentation
35 slides from Corona Remedies's earnings presentation, May 11, 2026
Slide 1: Cover letter to stock exchanges: presentation to analysts/investors
May 11, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: C
Slide 2: CORONA Remedies Limited Investor Presentation: May 2026
CORONA Remedies Limited Investor Presentation: May 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Annexures Management
Slide 5: Key Highlights for Q4 & FY26
Key Highlights for Q4 & FY26 Financial Highlights Return Ratios Key Highlights Reported healthy revenue growth of 20.2% in Q4FY26 (Y-o-Y) FY26 (Y-o-Y) FY26 Q4 and 17.3% in FY26 on a Y-o-Y basis, supported by brand strength and execution excellence. INR 353.1 Cr INR 1,403.2 Cr 40.8% RE V E NU E S
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (INR Crores) Q4FY26 Q4FY25 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 353.1 293.7 20.2% 1,403.2 1,196.4 17.3% Cost of Goods Sold 66.2 56.9 260.9 236.5 Gross Profit 286.9 236.8 1,142.2 959.9 Gross Margin (%) 81.2% 80.6% 81.4% 80.2% Employee Cost
Slide 7: Consolidated Balance Sheet
Consolidated Balance Sheet Assets ( INR Crores) Mar-26 Mar-25 Equity & Liabilities (INR Crores) Mar-26 Mar-25 Non - Current Assets 856.8 591.0 Total Equity 746.9 606.3 Property, plant and equipment 291.1 198.7 Share Capital 61.2 61.2 Capital work-in-progress 143.1 186.0 Other Equity 685.7 545.2 Inta
Slide 8: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Particulars (INR Crores) FY26 FY25 Profit Before Tax 240.4 198.5 Adjustments for: Non - Cash Items / Other Investment or Financial Items 44.4 52.3 Operating profit before working capital changes 284.8 250.8 Changes in working capital -5.9 -17.1 Cash generate
Slide 9: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 Annexures Management
Slide 10: CORONA's 3C Philosophy
CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growt
Slide 11: Journey over the years
Journey over the years Acquisition of 7 brands from Bayer Zydus Pharma Ltd Listing on NSE & BSE in In -licensing arrangement with Ferring December 2025 Launch of 1st cardiological Pharmaceuticals Private Limited to Received EAEU GMP Founded in 2004 and division: Wellness market certain p
Slide 12: CORONA Remedies at a Glance
CORONA Remedies at a Glance 17.3% Jumped 5 95.9% 71.9% Revenue growth 1 ranks in 3 Revenue from India Chronic portfolio years Business contribution 2.0x growth compared Over MAT Mar-23 to for FY26 for FY26 to IPM 1 MAT Mar-26 EU-GMP, EAEU- #5 in Women’s Healthcare Strategic acquisition of 76 Brands
Slide 13: CORONA's Competitive Edge Lies in Execution Excellence
CORONA’s Competitive Edge Lies in Execution Excellence Fastest Growing in Indian Pharmaceutical Market (IPM) 17.2% Revenue MAT Growth— Fastest Growth Among Top 30 Indian Pharma Peers, Climbing 5 Ranks in 3 Years* Market Share Gains & New Launches Consistently delivering volume growth with market sha
Slide 14: Quality Focused State of the Art Manufacturing Facilities
Quality Focused State of the Art Manufacturing Facilities Himachal Pradesh Total Installed Capacity Gujarat Installed capacity of ~403 Mn tablets/capsules & 10 Mn liquid Installed capacity of ~1.25 bottles Bn* tablets/capsules & 20 Formulations* WHO-GMP & Uganda NDA Mn sachets certifications Certifi
Slide 15: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 Annexures Management
Slide 16: Indian Pharmaceutical Market: High-Growth Landscape
Indian Pharmaceutical Market : High-Growth Landscape IPM is poised to grow at CAGR of 8-9% till FY30 Growth drivers for domestic formulations industry INR Trillion 3.1 2.3 Improving life expectancy and changing 2.1 1.8 1.9 demographic profile 1.5 1.5 01 Rising prevalence of chronic diseases FY20 FY2
Slide 17: CORONA Remedies: Demonstrated 2.0x Growth compared to IPM
CORONA Remedies: Demonstrated 2.0x Growth compared to IPM CORONA has grown at 2.0x compared to IPM growth [1] Growth driven by volume, price and new product launches 1.4x 17.2% 7.8% 2.6x 6.4% 5.4% 8.6% 4.6x 3.0% 2.5% 0.7% CORONA Remedies IPM Average [1] Volume Growth Price Growth NI (2) growth IPM C
Slide 18: Cementing position in Chronic segment with focus on four Key Therapies
Cementing position in Chronic segment with focus on four Key Therapies Women’s Healthcare Cardio-Diabeto Pain Management Urology CORONA Remedies vs. 2.9x 1.5x 1.7x 4.7x IPM CAGR [1] 20.3% 15.9% 19.0% 76.5% 10.9% 11.3% 7.1% 16.1% IPM CORONA IPM CORONA IPM CORONA IPM CORONA Women’s Healthcare Cardio-D
Slide 19: Focussed presence in the Middle of the Pyramid segment
Focussed presence in the “Middle of the Pyramid’’ segment Specialty-wise prescription split IPM 8% Super 12% Strategic focus on Specialist specialist and super- specialist doctors in the ‘middle of the pyramid’; resulting in a higher prescription contribution compared with IPM 35% 35% Specialist 55%
Slide 20: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 Annexures Management
Slide 21: Engine Brands approach with Successful Scaling Up of Brands
“Engine” Brands approach with Successful Scaling Up of Brands 32 Engine Brands Established track record of building and scaling brands Brands with Sales ~76% 32 >INR 10 Crs 38 Contribution to Domestic Sales over MAT Mar-23 to MAT Mar-26 2 ~19% 0 8 CAGR over 3 MAT Mar-23 to MAT Mar-26 11 10 Brands To
Slide 22: Acquisition & Strategic Collaborations for India Business
Acquisition & Strategic Collaborations for India Business Strategic collaborations for India Significantly scaled-up acquired brands Business Sr. No Acquired From Brands GSK Pharmaceuticals Limited Dilo Ferring Pharmaceuticals, Switzerland 1 Stelbid In-Licensing Arrangement for certain products in G
Slide 23: Strategic Portfolio Diversification & Brand Development
Strategic Portfolio Diversification & Brand Development Chronic v/s Acute 28.1% Chronic 45.3% 10 Acute Accelerating growth in 54.7% FY16 Years FY26 chronic therapies - 71.9% Outperforming the IPM Womens Healthcare 23.7% Pain Management Therapy Wise 27.5% 10 32.8% Cardio Diabeto Strengthening focus o
Slide 24: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 Annexures Management
Slide 25: Future Growth Strategies
CORONA Remedies Limited Future Growth Strategies • Improve MR productivity, expanding prescriber base and increasing the number of products Increase market share 1 within the domestic prescribed per prescriber • Intensify engagement with super-specialist prescribers in metro, semi-metro, and urban c
Slide 26: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q4 and FY26 Annexures Management
Slide 27: Professional Senior Management Leading the Way
Professional Senior Management Leading the Way Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Managing Director & CEO Joint Managing Director Whole-Time Director Over 2 decades of experience in the Over 2 decades of experience in the Over 2 decades of experience in th
Slide 28: Experienced Board of Directors
Experienced Board of Directors Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Dr. Kiritkumar Laxmidas Mehta Managing Director & CEO Joint Managing Director Whole-Time Director Chairman and Non-Executive Director Ameetkumar Hiranyakumar Desai Monica Kanuga Shirish Gund
Slide 29: ESG @ CORONA Remedies
ESG @ CORONA Remedies • Existing solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park Spread across E 11.9 Acres which saves significant electricity cost • Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearing un-ironed clothes • Effl
Slide 30: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Profit and Loss (INR Crores) FY26 FY25 FY24 FY23 Revenue from Operations 1,403.2 1,196.4 1,014.5 884.1 Cost of Goods Sold 260.9 236.5 226.8 211.0 Gross Profit 1,142.2 959.9 787.6 673.1 Gross Margin (%) 81.4% 80.2% 77.6% 76.1% Employee Cost 403.0 346.1
Slide 31: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Assets ( INR Crores) Mar-26 Mar-25 Mar-24 Mar-23 Equity & Liabilities (INR Crores) Mar-26 Mar-25 Mar-24 Mar-23 Non - Current Assets 856.8 591.0 540.7 303.5 Total Equity 746.9 606.3 480.4 408.5 Property, plant and equipment 291.1 198.7 191.0 184.1 Share Capital 6
Slide 32: Historical Consolidated Abridged Cash Flow Statement
Historical Consolidated Abridged Cash Flow Statement Abridged Cash Flow Statement (INR Crores) FY26 FY25 FY24 FY23 Net Profit Before Tax 240.4 198.5 118.5 110.9 Adjustments for: Non - Cash Items / Other Investment or Financial Items 44.4 52.3 46.9 22.6 Operating profit before working capital changes
Slide 33: Historical Financial Statement
Historical Financial Statement Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) 1,403.2 293.4 199.4 17% 1,196.4 +32% 240.0 +33% 1,014.5 149.4 884.1 154.7 128.0 90.5 84.9 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26* *Excludes onetime statutory impact of New Labor Code Rs.19.1
Slide 34: Historical Financial Ratios
Historical Financial Ratios ROCE (%) ROE (%) 41.3% 40.8% 29.2% 27.5% 31.2% 23.3% 28.4% 20.4% FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* OCF/EBITDA (%) Net working Capital Days 101.3% 31 27 80.2% 79.4% 78.2% 23 24 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 *ROE and ROCE for FY26 is annualised & Excludes
Slide 35: THANK YOU
THANK YOU For further information, please contact: CORONA Remedies Limited Strategic Growth Advisors Private Limited (SGA) CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / ta